Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05620576 · ClinicalTrials.gov registry record · Phase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
A Phase 2 study of Diabetic Peripheral Neuropathic Pain, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
- 20
- Study locations
NCT05620576: Completed Phase 2 study of Diabetic Peripheral Neuropathic Pain, sponsored by Eli Lilly and Company.
NCT05620576 is a Phase 2 study of Diabetic Peripheral Neuropathic Pain that has completed, run by Eli Lilly and Company. The registered enrollment target is 131 participants, below the 419-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05620576, a Phase 2 study of Diabetic Peripheral Neuropathic Pain, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to test the safety and efficacy of the study drug LY3857210 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Primary Outcome
The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0=no pain, and 10=pain as bad as you can imagine. Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3857210
Study Locations (20)
Florida
- Accel Research Sites- Clinical Research Unit - DeLand
- Suncoast Research Group - Miami
- University of Miami Don Suffer Clinical Research Building - Miami
- New Horizon Research Center - Miami
- Renstar Medical Research - Ocala
- Synexus Clinical Research US, Inc - Orlando - Orlando
- Synexus Clinical Research US, Inc. - Pinellas Park
Massachusetts
- Boston Clinical Trials - Boston
- ActivMed Practices and Research - Methuen
- MedVadis Research Corporation - Waltham
Arizona
- Synexus Clinical Research US, Inc. - Chandler
- Arizona Research Center - Phoenix
California
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
Connecticut
- CMR of Greater New Haven, LLC - Hamden
Georgia
- North Georgia Clinical Research - Woodstock
Idaho
- Rocky Mountain Clinical Research - Idaho Falls
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2022-11-14 |
| Est. Completion | 2023-08-01 |
| Phase | Phase 2 |
What the finished NCT05620576 record still lists
NCT05620576 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 419-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Diabetic Peripheral Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05620576 names 20 study sites across 10 states, led by Florida, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT05620576 about?
NCT05620576 is a clinical study titled "A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).". This study is being done to test the safety and efficacy of the study drug LY3857210 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chr...
What is the current status of trial NCT05620576?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2022-11-14. Estimated completion is 2023-08-01.
What conditions does trial NCT05620576 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathic Pain.
What interventions are being tested in trial NCT05620576?
The interventions under investigation include: Placebo (DRUG), LY3857210 (DRUG).
Who is sponsoring clinical trial NCT05620576?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05620576 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Peripheral Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 2
-
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
RECRUITING · Phase 2
-
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
COMPLETED · Phase 2
-
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
RECRUITING · Phase 1
-
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI